Images List Premium Download Classic

Syndrome X

Syndrome X-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method for suppressing glucagon secretion of an sglt2 inhibitor
Astrazeneca Ab
May 18, 2017 - N°20170135981

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (...
Combination therapy for the treatment of diabetes
Janssen Pharmaceutica N.v.
May 11, 2017 - N°20170128414

The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.
Combination therapy for effecting weight loss and treating obesity
Janssen Pharmaceutica N.v.
May 04, 2017 - N°20170119730

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Syndrome X Patent Pack
Download + patent application PDFs
Syndrome X Patent Applications
Download + Syndrome X-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Syndrome X-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Insulin sensitisers and methods of treatment
Naia Metabolic, Inc.
March 23, 2017 - N°20170079960

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease. The ...
Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
March 16, 2017 - N°20170073286

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Treatment of metabolic disorders in canine animals
Boehringer Ingelheim Vetmedica Gmbh
December 15, 2016 - N°20160361289

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia ...
Syndrome X Patent Pack
Download + patent application PDFs
Syndrome X Patent Applications
Download + Syndrome X-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Syndrome X-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
Metabasis Therapeutics, Inc.
September 15, 2016 - N°20160263132

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight ...
Engineered polypeptides having enhanced duration of action and reduced immunogenicity
Metabasis Therapeutics, Inc.
July 21, 2016 - N°20160207974

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Pharmaceutical compounds
Isis Innovation Ltd
June 02, 2016 - N°20160151347

The present invention provides hydroxychloroquine or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of systolic heart failure, sincus tachycardia, cardiac syndrome x and/or essential hypertension.
Engineered polypeptides having enhanced duration of action
Aegerion Pharmaceuticals, Inc.
May 19, 2016 - N°20160137709

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Methods and formulations for modulating lyn kinase activity and treating related disorders
Melior Pharmaceuticals I, Inc.
May 19, 2016 - N°20160136165

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, ...
Combination therapy for the treatment of diabetes
Janssen Pharmaceutica N.v.
March 31, 2016 - N°20160089360

The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.
Highly soluble leptins
Aegerion Pharmaceuticals, Inc.
March 24, 2016 - N°20160083446

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii). Additional diseases and disorders which can be treated by the compounds and ...
Syndrome X Patent Pack
Download + patent application PDFs
Syndrome X Patent Applications
Download + Syndrome X-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Syndrome X-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, method of preparing same and pharmaceutical composition ...
Hyundai Pharm Co., Ltd
January 28, 2016 - N°20160024063

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the ...
Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
December 03, 2015 - N°20150344389

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
December 03, 2015 - N°20150344388

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
Formulation for co-therapy treatment of diabetes
Janssen Pharmaceutica Nv
December 03, 2015 - N°20150342926

The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x.
Compositions containing berberine and pantethine and methods for treatment of lipid metabolism disorders
Janssen Pharmaceutica Nv
September 17, 2015 - N°20150258078

The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as hypercholesterolemia, hyperlipidemia, elevated triglycerides, syndrome x (metabolic syndrome), hyperglycemia, diabetes, cardiovascular disease and the like as well as disorders of lipid metabolism with failed response to standard therapies (for example statins) or any other disease or condition associated with lipids and lipid ...
Method of weight reduction
Vera Pharmaceuticals Ltd
June 25, 2015 - N°20150174108

The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome x, hyper-glycaemia, vascular disease and kidney disease. The ...
Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
Metabasis Therapeutics, Inc.
June 18, 2015 - N°20150166590

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight ...
Treatment of metabolic disorders in feline animals
Boehringer Ingelheim Vetmedica Gmbh
June 18, 2015 - N°20150164856

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, ...
Loading